David Sponsel Sells 36,256 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 36,256 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $11.42, for a total transaction of $414,043.52. Following the completion of the transaction, the executive vice president now directly owns 735,074 shares in the company, valued at $8,394,545.08. This represents a 4.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Sponsel also recently made the following trade(s):

• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The shares were sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Price Performance

Shares of ATEC stock opened at $11.95 on Thursday. The company has a market cap of $1.69 billion, a P/E ratio of -9.34 and a beta of 1.43. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The stock’s 50-day moving average is $10.24 and its 200 day moving average is $8.11. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Polar Asset Management Partners Inc. lifted its position in Alphatec by 381.9% during the third quarter. Polar Asset Management Partners Inc. now owns 621,224 shares of the medical technology company’s stock valued at $3,454,000 after acquiring an additional 492,324 shares during the last quarter. AlphaCentric Advisors LLC acquired a new position in shares of Alphatec during the third quarter worth $2,057,000. Bank of New York Mellon Corp lifted its holdings in shares of Alphatec by 119.3% during the 4th quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company’s stock valued at $6,079,000 after purchasing an additional 360,258 shares during the last quarter. Congress Asset Management Co. boosted its position in shares of Alphatec by 235.4% in the 4th quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company’s stock worth $3,993,000 after purchasing an additional 305,296 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after buying an additional 297,850 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Barclays lifted their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Finally, Needham & Company LLC increased their target price on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and an average target price of $17.56.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.